Does the media prefer ACRS or RCUS?

In the previous week, Arcus Biosciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for Arcus Biosciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat Arcus Biosciences' score of 0.34 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ACRS or QURE?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Aclaris Therapeutics' score of 0.50 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ACRS or CLDX?

In the previous week, Celldex Therapeutics had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 5 mentions for Celldex Therapeutics and 2 mentions for Aclaris Therapeutics. Celldex Therapeutics' average media sentiment score of 0.76 beat Aclaris Therapeutics' score of 0.50 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GMTX or ACRS?

Aclaris Therapeutics has a consensus price target of $11.33, indicating a potential upside of 106.06%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 3.11

Aclaris Therapeutics (ACRS) Competitors

$5.50 +0.10 (+1.85%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.38 -0.12 (-2.11%)

As of 09/18/2026 07:30 PM Eastern

Compare

ACRS vs. RCUS, QURE, CLDX, GMTX, and ZLAB

Should you buy Aclaris Therapeutics stock or one of its competitors? Aclaris Therapeutics's main competitors and comparable companies include Arcus Biosciences (RCUS), uniQure (QURE), Celldex Therapeutics (CLDX), Gemini Therapeutics (GMTX), and Zai Lab (ZLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aclaris Therapeutics compare to Arcus Biosciences?

Aclaris Therapeutics (NASDAQ:ACRS) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Arcus Biosciences has a net margin of -393.16% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Aclaris Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A
Arcus Biosciences	$247M	13.04	-$353M	-$3.90	N/A

Aclaris Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, Arcus Biosciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for Arcus Biosciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat Arcus Biosciences' score of 0.34 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics currently has a consensus target price of $11.33, suggesting a potential upside of 106.06%. Arcus Biosciences has a consensus target price of $38.30, suggesting a potential upside of 51.40%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aclaris Therapeutics beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to uniQure?

Aclaris Therapeutics (NASDAQ:ACRS) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Aclaris Therapeutics' score of 0.50 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aclaris Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A
uniQure	$18.67M	163.46	-$198.97M	-$4.01	N/A

Aclaris Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Aclaris Therapeutics currently has a consensus price target of $11.33, suggesting a potential upside of 106.06%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 47.73%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Aclaris Therapeutics has a net margin of -921.50% compared to uniQure's net margin of -1,350.73%. Aclaris Therapeutics' return on equity of -61.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
uniQure	-1,350.73%	-111.96%	-29.01%

Summary

Aclaris Therapeutics beats uniQure on 11 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Celldex Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Celldex Therapeutics' return on equity of -52.35% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Aclaris Therapeutics currently has a consensus target price of $11.33, indicating a potential upside of 106.06%. Celldex Therapeutics has a consensus target price of $56.42, indicating a potential upside of 47.53%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aclaris Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Celldex Therapeutics had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 5 mentions for Celldex Therapeutics and 2 mentions for Aclaris Therapeutics. Celldex Therapeutics' average media sentiment score of 0.76 beat Aclaris Therapeutics' score of 0.50 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Aclaris Therapeutics has higher revenue and earnings than Celldex Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A
Celldex Therapeutics	$1.54M	1,949.99	-$258.76M	-$4.35	N/A

98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Celldex Therapeutics beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Aclaris Therapeutics has a consensus price target of $11.33, indicating a potential upside of 106.06%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Gemini Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat Gemini Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Aclaris Therapeutics	Positive

Gemini Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Gemini Therapeutics' return on equity of -38.78% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Aclaris Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A

Summary

Aclaris Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Aclaris Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.35	-$175.54M	-$1.71	N/A
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A

Zai Lab has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Zai Lab currently has a consensus price target of $37.25, indicating a potential upside of 44.94%. Aclaris Therapeutics has a consensus price target of $11.33, indicating a potential upside of 106.06%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Zai Lab. Aclaris Therapeutics' average media sentiment score of 0.50 beat Zai Lab's score of -0.45 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Aclaris Therapeutics	Positive

Zai Lab has a net margin of -41.86% compared to Aclaris Therapeutics' net margin of -921.50%. Zai Lab's return on equity of -27.43% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Zai Lab on 11 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$755.05M	$3.92B	$7.26B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-9.48	14.30	275.79	25.40
Price / Sales	98.21	1,415.50	695.58	114.47
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	6.47	15.45	10.46	6.33
Net Income	-$64.92M	-$22.86M	$3.49B	$358.33M
7 Day Performance	3.38%	-1.21%	0.59%	1.12%
1 Month Performance	-14.60%	-4.42%	-2.01%	-2.67%
1 Year Performance	187.96%	37.81%	18.09%	6.01%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	2.1632 of 5 stars	$5.50 +1.9%	$11.33 +106.1%	+182.1%	$755.05M	$7.83M	N/A	73
RCUS Arcus Biosciences	3.1714 of 5 stars	$24.04 -2.2%	$38.30 +59.3%	+102.9%	$3.13B	$117M	N/A	601	Positive News Analyst Forecast
QURE uniQure	3.6917 of 5 stars	$44.93 +0.9%	$65.00 +44.7%	+198.5%	$3.12B	$16.10M	N/A	221
CLDX Celldex Therapeutics	2.1225 of 5 stars	$39.18 +6.2%	$56.42 +44.0%	+47.5%	$3.08B	$1.54M	N/A	198	News Coverage
GMTX Gemini Therapeutics	N/A	$70.06 -5.5%	N/A	+13.3%	$3.04B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. RCUS, QURE, CLDX, GMTX, and ZLAB

How does Aclaris Therapeutics compare to Arcus Biosciences?

Summary

How does Aclaris Therapeutics compare to uniQure?

Summary

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Summary

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Summary

How does Aclaris Therapeutics compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. RCUS, QURE, CLDX, GMTX, and ZLAB

How does Aclaris Therapeutics compare to Arcus Biosciences?

Is ACRS or RCUS more profitable?

Which has preferable valuation & earnings, ACRS or RCUS?

Which has more risk & volatility, ACRS or RCUS?

Does the media prefer ACRS or RCUS?

Do analysts prefer ACRS or RCUS?

Do insiders and institutionals have more ownership in ACRS or RCUS?

Summary

How does Aclaris Therapeutics compare to uniQure?

Does the media refer more to ACRS or QURE?

Do insiders and institutionals hold more shares of ACRS or QURE?

Which has preferable valuation and earnings, ACRS or QURE?

Which has more volatility and risk, ACRS or QURE?

Do analysts prefer ACRS or QURE?

Is ACRS or QURE more profitable?

Summary

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Is ACRS or CLDX more profitable?

Do analysts rate ACRS or CLDX?

Does the media refer more to ACRS or CLDX?

Which has more risk and volatility, ACRS or CLDX?

Which has higher valuation & earnings, ACRS or CLDX?

Do institutionals and insiders believe in ACRS or CLDX?

Summary

How does Aclaris Therapeutics compare to Gemini Therapeutics?

Do analysts prefer GMTX or ACRS?

Do institutionals and insiders hold more shares of GMTX or ACRS?

Which has more volatility and risk, GMTX or ACRS?

Does the media favor GMTX or ACRS?

Is GMTX or ACRS more profitable?

Which has better earnings & valuation, GMTX or ACRS?

Summary

How does Aclaris Therapeutics compare to Zai Lab?

Which has stronger earnings & valuation, ZLAB or ACRS?

Which has more risk & volatility, ZLAB or ACRS?

Do analysts prefer ZLAB or ACRS?

Does the media prefer ZLAB or ACRS?

Is ZLAB or ACRS more profitable?

Do institutionals and insiders believe in ZLAB or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools